When Medtronic said in early June that it had filed to put its Hugo robot into general and gynecologic surgery, the reaction across the industry was instant: the company is finally coming for Intuitive’s home turf. That part is true, and it is also the least interesting thing about the filing. The argument everyone is about to have is whether Hugo is as good as da Vinci. Having helped build one of these systems myself, I think that is the wrong fight, and the way Medtronic packaged the announcement tells me the company knows it too.
What Medtronic actually filed
On June 3, Medtronic announced 510(k) submissions to clear Hugo for general surgery, including hernia repair, and for gynecologic procedures. Those two specialties are where most robotic surgery happens. By Intuitive’s own 2024 figures, da Vinci ran about 1.25 million general surgery cases and 468,000 gynecologic ones in the United States, against roughly 201,000 in urology. Hugo is cleared here only for urology so far, from December 2025, and is in commercial use at U.S. medical centers. So this is Medtronic reaching for a slice of the market that is an order of magnitude larger than where it competes today. MedTech Dive reported the filings and the volume breakdown.
The question that actually decides this
Whether Hugo wins or loses a head-to-head against da Vinci on any given case is not what settles this market. A second credible platform widens the population of surgeons and hospitals that can offer robotic surgery at all. The hard part of a complex laparoscopic procedure lives in the surgeon’s wrists, and a robot moves that difficulty into the machine. That is how robotics grew the number of surgeons who can perform a minimally invasive prostatectomy from a few dozen worldwide to tens of thousands. The honest comparison was never robot versus the small expert group who can do it by hand. It was robot versus open surgery, because open surgery is what most of those patients would otherwise have gotten.
A second platform pushes that access curve further still: more installed sites, real price competition, more surgeons trained on a system, more procedures that move from open to minimally invasive. If you are building any robotic or capital surgical platform, this is the positioning lesson. Hospitals are not weighing your robot against a world-class manual surgeon they do not employ. They are weighing whether they can offer a minimally invasive option to patients who would otherwise go under the knife the old way. Position against that counterfactual, not against the category leader’s best day.
The tell is everything filed alongside the robot
Look at what shared the press release. Medtronic did not just file for two indications. It also won 510(k) clearance for its ProGrip self-gripping mesh for robotic ventral hernia repair, a procedure performed nearly 470,000 times a year in the United States, and it filed a separate 510(k) for a LigaSure energy instrument built to run on Hugo. The robot is the capital purchase a hospital makes once. The mesh, the energy device, the staplers, the sealing instruments are what get consumed on every case and reordered for as long as the system runs. Medtronic has sold surgical consumables for decades. Filing the indication and the disposable stack in the same breath is a company telling you the robot is the entry point and the workflow around it is the business.
Founders selling expensive boxes outside the operating room face the same arithmetic. Diagnostics learned this years ago: place the analyzer cheaply, make the margin on the reagents that run through it. The instrument opens the door; the consumable pays the rent. Whether you are shipping a surgical robot, a sequencer, a tissue sealer, or an industrial cell, the number that decides the business is rarely the sticker price. It is what gets consumed, reordered, and serviced after the thing is installed, and whether you control that stream or hand it to someone else.
Dave’s take
When I was building a surgical robot at Galen, the questions that mattered were never about beating a competitor on a spec sheet. They were about which surgeons could realistically adopt the thing, and what each procedure would cost to run. Medtronic’s filing is built for exactly those two questions. If you are raising on the elegance of your hardware, you are pitching the part a buyer weighs last. Pitch the access you create, and the recurring revenue that follows each case you make possible.
I’m here to help you scale.
Work With DavePrefer a smaller first step? Book a $500 one-hour consultation →
Dave Saunders is the founder of Base Reality Group and a Fractional CPO for hard-tech founders. He was a founder and operator at Galen Robotics, where the surgical-robotics platform earned FDA De Novo authorization in 2023, and he managed a 35-patent portfolio licensed from Johns Hopkins. He wrote Founders Who Finish and publishes The Build. More about Dave →